Ann: Lumos Awarded National Contract with MediGroup for FebriDx, page-22

3.8 will be it until the retail offer and underwriting is finished next week.

After that, expect sustained rises - how much depends on Q1 FebriDx sales.

Sales have been better than expected.

Expect new IP / manufacturing contracts to be announced by end of year.

ViraDx likely to be ended as undercut by Chinese - big focus on moving existing stock before final decision next year.

There are confirmed ViraDx sales.

Pretty much all I can tell you from the meeting with Doug and Barry yesterday.

Other announcements are expected in the next 12 months, but I cannot say what until contracts are signed, but it would be unfathomable if they fell over.